News
KLRS
1.660
-12.63%
-0.240
Kalaris Therapeutics Is Maintained at Market Outperform by Citizens
Dow Jones · 1d ago
Kalaris Therapeutics Price Target Cut to $20.00/Share From $25.00 by Citizens
Dow Jones · 1d ago
Citizens Maintains Market Outperform on Kalaris Therapeutics, Lowers Price Target to $20
Benzinga · 1d ago
Kalaris Therapeutics price target lowered to $20 from $25 at Citizens
TipRanks · 1d ago
Kalaris Therapeutics Q3 EPS $(0.46) Beats $(0.51) Estimate
Benzinga · 2d ago
Kalaris Therapeutics Reports Q3 Net Loss
NASDAQ · 2d ago
Kalaris Therapeutics, Inc. GAAP EPS of -$0.46 beats by $0.05
Seeking Alpha · 2d ago
*Kalaris Therapeutics: Potential Initiation of a Phase 3 Program Now Expected in 2028, Resulting in Extension of Anticipated Cash Runway Into 2028 and Beyond Preliminary Phase 1b/2 Data Readout >KLRS
Dow Jones · 2d ago
*Kalaris Therapeutics: Preliminary Data From Ongoing Phase 1b/2 Study of TH103 in nAMD Now Expected 2H 2027 >KLRS
Dow Jones · 2d ago
Press Release: Kalaris Reports Third Quarter 2026 Financial Results and Provides Business Update
Dow Jones · 2d ago
Weekly Report: what happened at KLRS last week (1102-1106)?
Weekly Report · 3d ago
Weekly Report: what happened at KLRS last week (1026-1030)?
Weekly Report · 11/02 10:20
Weekly Report: what happened at KLRS last week (1019-1023)?
Weekly Report · 10/26 10:20
Weekly Report: what happened at KLRS last week (1012-1016)?
Weekly Report · 10/19 10:19
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 10/15 12:12
Weekly Report: what happened at KLRS last week (1005-1009)?
Weekly Report · 10/12 10:25
Weekly Report: what happened at KLRS last week (0928-1002)?
Weekly Report · 10/05 10:24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 09/30 12:05
Weekly Report: what happened at KLRS last week (0921-0925)?
Weekly Report · 09/28 10:19
Weekly Report: what happened at KLRS last week (0914-0918)?
Weekly Report · 09/21 10:20
More
Webull provides a variety of real-time KLRS stock news. You can receive the latest news about Kalaris Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About KLRS
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).